Timothy Rolph Sells 31,250 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 31,250 shares of Akero Therapeutics stock in a transaction on Monday, January 27th. The stock was sold at an average price of $55.77, for a total value of $1,742,812.50. Following the sale, the insider now directly owns 170,237 shares of the company’s stock, valued at approximately $9,494,117.49. This trade represents a 15.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total transaction of $148,924.38.

Akero Therapeutics Stock Up 4.9 %

NASDAQ:AKRO traded up $2.53 on Wednesday, hitting $54.00. The stock had a trading volume of 3,613,883 shares, compared to its average volume of 2,167,465. Akero Therapeutics, Inc. has a 1 year low of $15.32 and a 1 year high of $58.40. The firm’s fifty day simple moving average is $29.31 and its two-hundred day simple moving average is $28.51. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The stock has a market cap of $3.77 billion, a P/E ratio of -14.40 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Analysts predict that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on AKRO. Citigroup upped their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley lifted their price objective on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research report on Tuesday. HC Wainwright upped their target price on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a report on Monday. Finally, Canaccord Genuity Group lifted their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $61.57.

Institutional Investors Weigh In On Akero Therapeutics

A number of hedge funds have recently made changes to their positions in AKRO. American Century Companies Inc. bought a new stake in Akero Therapeutics in the second quarter worth about $347,000. Renaissance Technologies LLC bought a new stake in shares of Akero Therapeutics in the 2nd quarter worth approximately $565,000. The Manufacturers Life Insurance Company lifted its stake in Akero Therapeutics by 26.1% in the second quarter. The Manufacturers Life Insurance Company now owns 107,172 shares of the company’s stock valued at $2,514,000 after purchasing an additional 22,195 shares during the last quarter. Handelsbanken Fonder AB grew its holdings in Akero Therapeutics by 12.4% during the third quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock valued at $574,000 after purchasing an additional 2,200 shares during the period. Finally, Creative Planning purchased a new stake in Akero Therapeutics in the third quarter worth $371,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.